Achieving dendritic cell subset-specific targeting in vivo by site-directed conjugation of targeting antibodies to nanocarriers
暂无分享,去创建一个
K. Landfester | V. Mailänder | S. Grabbe | J. Simon | M. Fichter | Cinja Kappel | Maximilian Brückner | J. Schunke | Gabor Kuhn
[1] K. Landfester,et al. The conjugation strategy affects antibody orientation and targeting properties of nanocarriers. , 2021, Nanoscale.
[2] K. Landfester,et al. Unraveling the In Vivo Protein Corona , 2021, Cells.
[3] N. Steinmetz,et al. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design , 2020, ACS nano.
[4] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.
[5] R. Baric,et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.
[6] Even Fossum,et al. Targeting Antigens to Different Receptors on Conventional Type 1 Dendritic Cells Impacts the Immune Response , 2020, The Journal of Immunology.
[7] K. Landfester,et al. Controlling protein interactions in blood for effective liver immunosuppressive therapy by silica nanocapsules. , 2020, Nanoscale.
[8] V. Mata-Haro,et al. Analysis of Swine Conventional Dendritic Cells, DEC205+CD172a+/−CADM1+, from Blood and Spleen in Response to PRRSV and PEDV , 2019, Viruses.
[9] I. Melero,et al. Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.
[10] G. Coukos,et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells , 2019, Journal of Immunotherapy for Cancer.
[11] Denicar Lina Nascimento Fabris Maeda,et al. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4+ T Cells to the Dengue Virus Envelope Protein Domain III , 2019, Front. Immunol..
[12] K. Landfester,et al. The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery , 2018, Front. Immunol..
[13] Steven J P McInnes,et al. Murine and Non-Human Primate Dendritic Cell Targeting Nanoparticles for in Vivo Generation of Regulatory T-Cells. , 2018, ACS nano.
[14] C. Figdor,et al. Dendritic cells in cancer immunotherapy , 2018, Nature Materials.
[15] Jesús Hernández,et al. Characterization and expression of DEC205 in the cDC1 and cDC2 subsets of porcine dendritic cells from spleen, tonsil, and submaxillary and mesenteric lymph nodes , 2018, Molecular Immunology.
[16] Teresa J. Feo,et al. Structural absorption by barbule microstructures of super black bird of paradise feathers , 2018, Nature Communications.
[17] Desiree Van Haute,et al. Challenges in realizing selectivity for nanoparticle biodistribution and clearance: lessons from gold nanoparticles. , 2017, Therapeutic delivery.
[18] D. Gabrilovich,et al. Dendritic cells in cancer: the role revisited. , 2017, Current opinion in immunology.
[19] K. Landfester,et al. Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses. , 2016, Biomaterials.
[20] Ian D. McGilvray,et al. Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[21] Kimberly S Butler,et al. Ligand-targeted theranostic nanomedicines against cancer. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[22] Zhiyuan Zhang,et al. Development and Applications of the Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) as a Bioorthogonal Reaction , 2016, Molecules.
[23] H. Schild,et al. Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma. , 2016, Nanomedicine.
[24] Matthew B. Dong,et al. Flow cytometric gating for spleen monocyte and DC subsets: differences in autoimmune NOD mice and with acute inflammation. , 2016, Journal of immunological methods.
[25] Keith E Maier,et al. Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] I. Bechmann,et al. CD11c‐positive cells from brain, spleen, lung, and liver exhibit site‐specific immune phenotypes and plastically adapt to new environments , 2015, Glia.
[27] Jian Ling,et al. Nanotoxicity of silver nanoparticles to red blood cells: size dependent adsorption, uptake, and hemolytic activity. , 2015, Chemical research in toxicology.
[28] J. Vallée,et al. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. , 2014, Nanoscale.
[29] K. Landfester,et al. Enhanced in vivo targeting of murine nonparenchymal liver cells with monophosphoryl lipid A functionalized microcapsules. , 2014, Biomacromolecules.
[30] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[31] Andrzej S Pitek,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[32] A. Roque,et al. Antibody-conjugated nanoparticles for therapeutic applications. , 2012, Current medicinal chemistry.
[33] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[34] Jinho Park,et al. Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.
[35] M. C. Stuart,et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[36] Isabelle Texier,et al. Copper-free click chemistry for highly luminescent quantum dot conjugates: application to in vivo metabolic imaging. , 2010, Bioconjugate chemistry.
[37] M. Wright,et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. , 2008, Blood.
[38] P. Carter,et al. Antibody-Drug Conjugates for Cancer Therapy , 2008, Cancer journal.
[39] R. Chari. Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.
[40] M. Gershwin,et al. The role of CD11c+ hepatic dendritic cells in the induction of innate immune responses , 2007, Clinical and experimental immunology.
[41] N. Shastri,et al. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] C. Figdor,et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. , 2005, Blood.
[43] Jennifer A. Prescher,et al. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. , 2004, Journal of the American Chemical Society.
[44] N. Van Rooijen,et al. Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response1 , 2004, The Journal of Immunology.
[45] Matti Hoch,et al. Advanced Drug Delivery Reviews , 2017 .
[46] V. Venditto,et al. Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.
[47] Juan L. Vivero-Escoto,et al. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. , 2009, Small.
[48] L. Steinhauer. Annual Review of Medicine. , 1958 .